Vericel Corp - FORM 8-K - February 28, 2011

Attached files

file filename
EX-99.1 - EX-99.1 - Vericel Corpa58833exv99w1.htm
 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported):
February 28, 2011
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
         
Michigan
(State or other
jurisdiction of
incorporation) 		  0-22025
(Commission File No.) 		  94-3096597
(I.R.S. Employer
Identification No.)
24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, Michigan 48106
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(734) 930-5555
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 2.02   Results of Operations and Financial Condition.
     On Feburary 28, 2011, we issued a press release announcing operating results for the quarter and six month period ended December 31, 2010. A copy of the press release is attached hereto as Exhibit 99.1.
     Pursuant to General Instruction B.2 of Form 8-K, this report and the exhibit are not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall this report and the exhibit be incorporated by reference into our filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such future filing.
Item 9.01   Financial Statements and Exhibits.
     (d) Exhibits.
         
Exhibit No.   Description
  99.1    
Press Release dated February 28, 2011

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 2011
         
  AASTROM BIOSCIENCES, INC.
 		  
  By:   /s/ Timothy M. Mayleben    
    Timothy M. Mayleben   
    Chief Executive Officer and President   
 

 

Vericel Corp Reports